Boston – July 27, 2015 – Cooley advised the underwriters on Celyad SA's initial public offering of American Depositary Shares (ADSs) and concurrent private placement in Europe. Celyad, based in Belgium, is a clinical-stage specialty biopharmaceutical company focused on changing the fields of cardiology and oncology by developing novel cell therapy treatment platforms called C-Cure and CAR-NKG2D. The company's ADSs trade on The NASDAQ Global Market under the symbol "CYAD."
UBS Securities LLC and Piper Jaffray & Co. acted as joint book-running managers of the global offering and as representatives of the several underwriters, including Petercam NV/SA, Bryan, Garnier & Co., LifeSci Capital, LLC and Lake Street Capital Markets, LLC.
About Cooley LLP
High-growth and established companies, investors and investment banks focused on technology and life sciences partner with Cooley on transformative deals and high-stakes matters, where innovation meets the law.
Cooley has 850 lawyers across 12 offices in the United States, China and Europe.